In this section
@article{Hillier:2005:10.1097/01.qai.0000159671.25950.74,
author = {Hillier, SL and Moench, T and Shattock, R and Black, R and Reichelderfer, P and Veronese, F},
doi = {10.1097/01.qai.0000159671.25950.74},
journal = {J Acquir Immune Defic Syndr},
pages = {1--8},
title = {In vitro and in vivo: the story of nonoxynol 9.},
url = {http://dx.doi.org/10.1097/01.qai.0000159671.25950.74},
volume = {39},
year = {2005}
}
TY - JOUR
AB - There is an urgent need to expand the range of interventions to prevent HIV transmission and acquisition, especially those that can be controlled by women. Microbicides, defined as antimicrobial products that can be applied topically for the prevention of HIV and other sexually transmitted infections, may offer one of the most promising preventive interventions, because they could be inexpensive, readily available, and widely acceptable. The first microbial product to be clinically evaluated contained Nonoxynol-9 (nonylpenoxypolyethoxyethanol [N-9]), a nonionic surfactant, as the active agent. This article presents a review of the in vitro, ex vivo, and animal model data on the safety of N-9 and a critical analysis of their predictive power based on the results of multiple safety and efficacy trials.
AU - Hillier,SL
AU - Moench,T
AU - Shattock,R
AU - Black,R
AU - Reichelderfer,P
AU - Veronese,F
DO - 10.1097/01.qai.0000159671.25950.74
EP - 8
PY - 2005///
SN - 1525-4135
SP - 1
TI - In vitro and in vivo: the story of nonoxynol 9.
T2 - J Acquir Immune Defic Syndr
UR - http://dx.doi.org/10.1097/01.qai.0000159671.25950.74
UR - https://www.ncbi.nlm.nih.gov/pubmed/15851907
VL - 39
ER -